Myris Therapeutics, Inc.

BiotechnologyBiotechnologyADCOncology

📍 Pittsburgh, PA, United States• Founded 2016

StreetZero Signal 70

Be the first to signal interest

About Myris Therapeutics, Inc.

Myris Therapeutics is a privately held life sciences biotech company with proprietary technology to enable ultra-high DAR ADCs by integrating traditional ADC engineering with next-generation polymer chemistry. Using their innovative platform technology, Myris is developing a pipeline of novel therapeutics for oncology. The company is headquartered in Pittsburgh, PA. Myris Therapeutics's predecessor company, BioHybrid Solutions, was founded to use sophisticated polymer chemistry to create NanoArmored protein-polymer conjugates.

LATEST FUNDINGPrivate Placement

$500K

Announced 2026-10-14

TOTAL RAISED$3.06M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Myris Therapeutics, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2016

HQPittsburgh, PA, United States

Industry

Biotechnology

Investors

Innovation Works Creative Destruction Lab National Science Foundation U.S. Department of Energy

Key highlights

Myris Therapeutics has raised $3.06M across 7 funding rounds.
Latest round was a Seed-II for $0.2M on December 21, 2023.
Backed by Innovation Works, Creative Destruction Lab, NSF, and U.S. Department of Energy.
Developing ultra-high DAR ADCs for oncology using polymer chemistry platform.
Predecessor BioHybrid Solutions received a $30M contract from the U.S. Department of Defense.